AXIM & MJNA Forge Alliance to Develop Water-Soluble Cannabinoid Breakthrough

In a groundbreaking move for the cannabinoid industry, AXIM Biotechnologies, Inc. (OTC: AXIM) has announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) to research and develop applications for AXIM's revolutionary water-soluble cannabinoid technology. At the heart of this partnership is AXIM's U.S. Patent No. 11,542,226 B2, titled "Polyfunctional Cannabinoids," which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body. As part of the transaction, AXIM has assigned MJNA a 50% right, title, and economic interest in this patent and all associated intellectual property, including rights to existing and future patents, licensing proceeds, and claims for past infringement. Concurrently, the companies entered into a Consulting Agreement where AXIM will provide MJNA with dedicated research and development services focused on commercializing the patent technology, with MJNA paying AXIM a monthly services fee of $62,500 and providing a $600,000 secured promissory note as consideration for the patent interest.

The technological breakthrough represented by this patent is substantial, featuring patented molecular engineering that links cannabinoids to complementary compounds, dramatically improving delivery mechanisms and therapeutic effectiveness. The engineered polyfunctional cannabinoids are more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption and therapeutic delivery. This enhanced solubility and bioavailability could lead to more potent responses with potentially lower therapeutic doses, avoiding toxic side effects associated with higher concentrations. Company leadership from both sides expressed strong optimism about the alliance, with AXIM President Catalina Valencia noting that the water solubility of CBD and other cannabinoids represents a significant development for improved administration and increased potency, potentially resulting in treatments for conditions like anxiety or seizures, likely through sublingual administration. MJNA Chairman and President Dr. Scott emphasized MJNA's confidence in AXIM's R&D capabilities and the company's existing knowledge and relationships in the cannabinoid market, viewing this alliance as a great fit with tremendous opportunity for both parties.

Beyond this specific cannabinoid technology, AXIM Biotechnologies has established itself as an innovative player in diagnostic medicine through its TearScan® platform, which enables clinicians to quantify tear biomarkers with laboratory-grade accuracy in office settings. The company has developed a vertically integrated diagnostic platform adaptable to detect a range of biomarkers, including applications for SARS-CoV-2 neutralizing antibodies and cancer biomarkers using novel methods like electrochemical/impedance spectroscopy. Notably, AXIM has also developed a non-invasive point-of-care assay for Parkinson's disease that uses a single tear sample to detect abnormal forms of alpha-synuclein, providing results in under 10 minutes without requiring invasive sample collection. This broader technological expertise positions AXIM as more than just a cannabinoid company, though the current alliance with MJNA through NEWMEDIAWIRE represents a significant step toward commercializing potentially transformative cannabinoid delivery technology that could revolutionize how these compounds are administered and absorbed in medical applications.